<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100107003014N20</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-10-28</date_registration>
      <primary_sponsor>Vice chancellor for research and technology, Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of hydroalcoholic extract of Ruscus hyrcanus in treatment of chronic venous insufficiency</public_title>
      <acronym></acronym>
      <scientific_title>Study of therapeutic effects of ointment containing hydro alcoholic extract of root and rhizome of Ruscus hyrcanus woronow in patients with chronic venous insufficiency (Grade 1 and 2 hemorrhoids); a randomized, double blind, controlled with placebo study.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-09-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/31108</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done through a random number table, Blinding description: Ointments made in "placebo" and "Drug" groups, are numbered in the list by the supervisor. After prescribing by the physician, the code of prescribed ointment will be entered into the questionnaire. Physician, Patient and investigator are not aware of the type of ointment.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Hemorrhoids grade 1. Condition 2: Hemorrhoids grade 2.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Ruscus extract 2% ointment/ 2 times daily/ 1 cm of the ointment/ For one month. Intervention 2: Control group:     ointment formolation without any drugs/ 1 cm of the ointment/ For one month.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is not any more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fateme Shamalizade Baii</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar azam university complex, Mazandaran University of Medical Sciences, Faculty of pharmacy, Km 18 Khazar abad road, Sari, Mazandaran, Iran</address>
        <city>sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815733971</zip>
        <telephone>+98 11 3354 3083</telephone>
        <email>sala@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Shahram Ala</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar Azam University Complex, Mazandaran University of Medical Sciences, Faculty of Pharmacy, Km 18 Khazar Abad Road, Sari, Mazandaran, Iran</address>
        <city>sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815733971</zip>
        <telephone>+98 11 3354 3083</telephone>
        <email>sala@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>at least 18 years old
first and second untreated hemorrhoids</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of allergic reactions to plants in this family
Pregnancy and Lactation
History of any anorectal surgery and non-pharmacological treatment of hemorrhoids
Ascetic, IBD, Inflammation and any illness that causes rectal bleeding
Thrombosis or external hypersensitivity of the hemorrhoid
Fissure or anal fistula
Hemorrhoids Grade 3 and 4
Anal abscess, port hypertension
Renal failure and any malignancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K64.0</hc_code>
      <hc_code>K64.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>First degree hemorrhoids</hc_keyword>
      <hc_keyword>Second degree hemorrhoids</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Ruscus extract 2% ointment/ 2 times daily/ 1 cm of the ointment/ For one month</i_keyword>
      <i_keyword>Control group:     ointment formolation without any drugs/ 1 cm of the ointment/ For one month</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Permanent pain. Timepoint: Measuring the amount of pain at the beginning of the study, the first week, the second, third and fourth weeks after the start of the study, is evaluated and recorded. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Pain during defecation. Timepoint: Measuring the amount of pain at the beginning of the study, the first week, the second, third and fourth weeks after the start of the study, is evaluated and recorded. Method of measurement: Visual analogue Scale.</prim_outcome>
      <prim_outcome>Anal bleeding. Timepoint: Measuring the amount of bleeding at the beginning of the study, the first week, the second, third and fourth weeks after the start of the study, is evaluated and recorded. Method of measurement: Visually and classified as: bloodless (0), low (1), moderate (2) and high (3).</prim_outcome>
      <prim_outcome>Strain during defecation. Timepoint: Measuring the amount of strain at the beginning of the study, the first week, the second, third and fourth weeks after the start of the study, is evaluated and recorded. Method of measurement: Mental scaling: defecation without strain(0), low(1), intermediate(2), high (3).</prim_outcome>
      <prim_outcome>Burning and itchy and unpleasant. Timepoint: Measuring the amount of Burning and itching at the beginning of the study, the first week, the second, third and fourth weeks after the start of the study, is evaluated and recorded. Method of measurement: Visual analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Side effect during treatment. Timepoint: The type of side effect measured during treatment at the first, second, third and fourth week after the start of treatment. Method of measurement: observation and according to questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research and technology, Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-06-21</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical</contact_name>
        <contact_address>moalem sq.vice chancelor of research, MAZUMS Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
